Papillary hyperplasia of the gallbladder in pancreaticobiliary maljunction represents a senescence-related lesion induced by lysolecithin.
Cellular senescence, an irreversible growth arrest, is considered to play as safeguard against malignant progression, though such a mechanism is speculative in human carcinogenesis. In gallbladder carcinoma, cholecystolithiasis and pancreaticobiliary maljunction (PBM) are major risk factors. Here, by using 113 surgically resected gallbladders and cultures of human gallbladder epithelial cells (HGECs) and gallbladder carcinoma cell line (TGBC2TKB), we examined carcinogenesis with respect to cellular senescence. Among 15 cases of PBM in which carcinoma was found in 4 cases, nonneoplastic gallbladder mucosa showed diffuse papillary hyperplasia (PHP). PHP was not found in gallbladders with cholecystolithiasis. Interestingly, PHP exhibited senescent features such as expression of p16(INK4A) and low cell proliferative activity. In contrast, EZH2, a polycomb group protein, was overexpressed in intraepithelial neoplasm and carcinoma in gallbladders with cholecystolithiasis. In PBM, EZH2 was expressed only in carcinoma foci but not in PHP. Cultured HGECs treated with lysolecithin, the level of which is elevated in gallbladder bile of PBM, showed increased expression of p16(INK4A) and senescence-associated beta-galactosidase. Conversely, enforced overexpression of EZH2 in senescent HGECs reduced p16(INK4A) expression. A knockdown of EZH2 in cultured TGBC2TKB cells increased p16(INK4a) expression. In conclusion, PHP in PBM may act as a barrier to malignant transformation for decades. EZH2 may be responsible for the escape from cellular senescence followed by malignant transformation in the gallbladder of PBM.
Yamaguchi
Junpei
J
Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Sasaki
Motoko
M
Harada
Kenichi
K
Zen
Yoh
Y
Sato
Yasunori
Y
Ikeda
Hiroko
H
Itatsu
Keita
K
Yokoyama
Yukihiro
Y
Ando
Hisami
H
Ohta
Tetsuo
T
Kubota
Akio
A
Shimizu
Koichi
K
Nimura
Yuji
Y
Nagino
Masato
M
Nakanuma
Yasuni
Y
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism / Q000473:pathology*; D002278:Carcinoma in Situ / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic / Q000378:metabolism / Q000473:pathology; D041761:Cholecystolithiasis / Q000150:complications / Q000473:pathology; D003135:Common Bile Duct / Q000002:abnormalities*; D003137:Common Bile Duct Diseases / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism; D000071221:Enhancer of Zeste Homolog 2 Protein; D004847:Epithelial Cells / Q000187:drug effects / Q000473:pathology; D005260:Female; D005704:Gallbladder / Q000378:metabolism / Q000473:pathology*; D005706:Gallbladder Neoplasms / Q000150:complications / Q000378:metabolism / Q000473:pathology; D020868:Gene Silencing; D006801:Humans; D006965:Hyperplasia; D008244:Lysophosphatidylcholines / Q000378:metabolism* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D010182:Pancreatic Diseases / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D010183:Pancreatic Ducts / Q000002:abnormalities*; D063151:Polycomb Repressive Complex 2; D014157:Transcription Factors / Q000378:metabolism; D055815:Young Adult
D019941:Cyclin-Dependent Kinase Inhibitor p16; D004268:DNA-Binding Proteins; D008244:Lysophosphatidylcholines; D014157:Transcription Factors; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2